BioAtla, Inc. (BCAB)
|Net Income (ttm)||-20.76M|
|Trading Day||January 15|
|Day's Range||44.97 - 48.15|
|52-Week Range||31.02 - 48.15|
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, to...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...
BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based thera...
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based thera...
San Diego, California-based BioAtla was founded to develop conditionally active biologics that 'exploit characteristic pH differences between the tumor microenvironment and healthy tissue.'
BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
BioAtla, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).
BioAtla, a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatoc... [Read more...]
|IPO Date |
Dec 16, 2020
Jay M. Short
|Stock Exchange |
|Ticker Symbol |
In 2019, BioAtla's revenue was $5.20 million, a decrease of -51.07% compared to the previous year's $10.63 million. Losses were -$29.79 million, 2.81% more than in 2018.
According to 4 analysts, the average rating for BioAtla stock is "Buy." The 12-month stock price forecast is 50.00, which is an increase of 10.18% from the latest price.